MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1007/s12185-024-03912-y

Медицинская библиотека · International journal of hematology · 2025

Clinical practice guidelines for management of disseminated intravascular coagulation in Japan 2024. Part 3: solid cancers and vascular abnormalities.

Seki Yoshinobu, Okamoto Kohji, Ikezoe Takayuki, Yamakawa Kazuma, Madoiwa Seiji, Uchiyama Toshimasa, Asakura Hidesaku, Yamada Shinya, Koga Shin, Ishikura Hiroyasu, Ito Takashi, Iba Toshiaki, Uchiba Mitsuhiro, Kawasaki Kaoru, Kawano Noriaki, Gando Satoshi, Kushimoto Shigeki, Sakamoto Yuichiro, Tamura Toshihisa, Nishio Kenji, Hayakawa Mineji, Matsumoto Takeshi, Mayumi Toshihiko, Wada Hideo, Committee of the Clinical Practice Guidelines for Disseminated Intravascular Coagulation 2024, the Japanese Society on Thrombosis and Hemostasis

СтатьяКлинические рекомендацииОбзорПеревод в очереди

Аннотация

This study discusses disseminated intravascular coagulation (DIC) associated with solid cancers and various vascular abnormalities, both of which generally exhibit chronic DIC patterns. Solid cancers are among the most significant underlying diseases that induce DIC. However, the severity, bleeding tendency, and progression of DIC vary considerably depending on the type and stage of the cancer, making generalization difficult. Moreover, during the process of creating these guidelines, it became apparent that despite solid cancers being a major underlying condition for DIC, there is a lack of high-quality research on DIC associated with solid cancers. Nevertheless, we developed recommendations for clinical questions (CQs) regarding the use of heparin and recombinant thrombomodulin. Additionally, statements concerning these five questions were provided. DIC associated with various vascular abnormalities, is characterized by hyperfibrinolytic activity and linked to underlying conditions such as aortic aneurysm, aortic dissection, vasculitis syndromes, and vascular malformations. These conditions must always be considered differential diagnoses when unexplained thrombocytopenia or bleeding tendencies are observed. Although no evidence was found to support the assignment of recommendation levels, three statements were made. However, traumatic vascular abnormalities have not been discussed in this context.

Для цитирования: Seki Yoshinobu, Okamoto Kohji, Ikezoe Takayuki, Yamakawa Kazuma, Madoiwa Seiji, Uchiyama Toshimasa, Asakura Hidesaku, Yamada Shinya, Koga Shin, Ishikura Hiroyasu, Ito Takashi, Iba Toshiaki, Uchiba Mitsuhiro, Kawasaki Kaoru, Kawano Noriaki, Gando Satoshi, Kushimoto Shigeki, Sakamoto Yuichiro, Tamura Toshihisa, Nishio Kenji, Hayakawa Mineji, Matsumoto Takeshi, Mayumi Toshihiko, Wada Hideo, Committee of the Clinical Practice Guidelines for Disseminated Intravascular Coagulation 2024, the Japanese Society on Thrombosis and Hemostasis. Clinical practice guidelines for management of disseminated intravascular coagulation in Japan 2024. Part 3: solid cancers and vascular abnormalities.. International journal of hematology. 2025. DOI: 10.1007/s12185-024-03912-y.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.